Early Phase Clinical Trials in Oncology

Early Phase Clinical Studies

We participate in first-in-human studies and increasingly in expansion cohorts targeting specified patient populations either in collaboration with pharmaceutical companies or independently.

Genomic Prescreening of Patients

In collaboration with the Hartwig Medical Foundation we will start screening patients for eligibility in trials using Whole Genome Sequencing, allowing us to increase the likelihood of benefit for the patients we enroll into Early Phase Clinical trials.

Identifying Patient Characteristics of Trial Participants

Patients that choose to participate in Early Phase Clinical trials should derive some benefit and using this research we aim to increase our understanding of how to achieve optimal patient benefit.

We currently have 30+ clinical trials in our early phase trial portfolio.

Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S,
Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey
S, Geenen J, Eskens FA, Gil-Martin M, Mommers EC, Koper
NP, Aftimos P. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019 Jun 27

https://www.sciencedirect.com/science/article/pii/S1470204519303286?via%3Dihub

van der Biessen DA, van der Helm PG, Klein D, van der Burg S, Mathijssen RH, Lolkema MP, de Jonge MJ. Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation. Psychooncology. 2018 Jan;27(1):163-170. doi: 10.1002/pon.4487.

https://onlinelibrary.wiley.com/doi/10.1002/pon.4487

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FA, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017 Jun;7(6):610-619.

http://cancerdiscovery.aacrjournals.org/content/7/6/610.long

de Jonge M, de Weger VA, Dickson MA, Langenberg M, Le Cesne A, Wagner AJ, Hsu K, Zheng W, Macé S, Tuffal G, Thomas K, Schellens JH. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur J Cancer. 2017 May;76:144-151.

https://www.sciencedirect.com/science/article/pii/S095980491730730X?via%3Dihub

Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J, Tabernero J. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res. 2013 Nov 15;19(22):6296-304.

http://clincancerres.aacrjournals.org/content/19/22/6296.long

We have an active collaboration with prof. C. van der Rijt, specialist Palliative care

We have an active collaboration with prof. A.H.J. Mathijssen, specialist Medical Oncology/ Clinical Pharmacology

We have an active collaboration with prof. W. Dinjens, Molecular Pathology department

Principle Investigators of phase I trials

• Ferry Eskens (chair)
• Sander Bins
• Maja de Jonge
• Debbie Robbrecht
• Henk Verheul
  
  

Nurse Practitioners

• Diane van der Biessen
• Andrea van Puffelen